pirtobrutinib - Profile

What are the generic drug sources for pirtobrutinib and what is the scope of freedom to operate?

Pirtobrutinib is the generic ingredient in one branded drug marketed by Loxo Oncol and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pirtobrutinib has one hundred and six patent family members in forty countries.

Summary for pirtobrutinib

International Patents:	105
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for pirtobrutinib

Constraining patent/regulatory exclusivity:

TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) WHO HAVE RECEIVED AT LEAST TWO PRIOR LINES OF THERAPY, INCLUDING A BTK INHIBITOR AND A BCL-2 INHIBITOR

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for pirtobrutinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-001	Jan 27, 2023		RX	Yes	No	10,918,622
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-001	Jan 27, 2023		RX	Yes	No	10,695,323		Y	Y
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-001	Jan 27, 2023		RX	Yes	No	10,464,905
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-001	Jan 27, 2023		RX	Yes	No	12,220,401		Y	Y
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-001	Jan 27, 2023		RX	Yes	No	10,342,780		Y	Y

EU/EMA Drug Approvals for pirtobrutinib

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Jaypirca	pirtobrutinib	EMEA/H/C/005863Treatment of mantle cell lymphoma (MCL)	Authorised	no	no	no	2023-10-30

International Patents for pirtobrutinib

Country	Patent Number	Title	Estimated Expiration
Croatia	P20201835
Finland	C20240004
Japan	7419437
Peru	20220507	COMPUESTOS UTILES COMO INHIBIDORES DE CINASA
United Kingdom	201613945

Supplementary Protection Certificates for pirtobrutinib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3390395	PA2024506	Lithuania		PRODUCT NAME: PIRTOBRUTINIBAS; REGISTRATION NO/DATE: EU/1/23/1738 20231030
3390395	2024/002	Ireland		PRODUCT NAME: PIRTOBRUTINIB; REGISTRATION NO/DATE: EU/1/23/1738 20231031
3390395	122024000010	Germany		PRODUCT NAME: PIRTOBRUTINIB; REGISTRATION NO/DATE: EU/1/23/1738 20231031
3390395	202440003	Slovenia		PRODUCT NAME: PIRTOBRUTINIB; NATIONAL AUTHORISATION NUMBER: EU/1/23/1738; DATE OF NATIONAL AUTHORISATION: 20231030; AUTHORITY FOR NATIONAL AUTHORISATION: EU
3390395	301262	Netherlands		PRODUCT NAME: PIRTOBRUTINIB; REGISTRATION NO/DATE: EU/1/23/1738 20231031

Pirtobrutinib: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Pirtobrutinib (formerly CB-049), developed by Loxo Oncology (a subsidiary of Eli Lilly), is an investigational Bruton's Tyrosine Kinase (BTK) inhibitor primarily targeted at B-cell malignancies, notably relapsed/refractory mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström’s macroglobulinemia (WM). Its unique reversible binding distinguishes it from covalent BTK inhibitors like ibrutinib, offering potential advantages in overcoming resistance and tolerability issues.

Currently in late-phase clinical trials, with potential approval anticipated within the next 12-24 months, pirtobrutinib's success hinges on clinical efficacy, safety, and competitive positioning. The drug presents significant investment opportunities, given the expanding market for BTK inhibitors, but also faces competition from established therapies and emerging pipeline drugs.

---

What Is the Current Market for BTK Inhibitors?

Segment	Market Size (USD millions)	Key Players	Market Penetration (2022)	Growth Rate (CAGR, 2023-2027)
MCL, CLL, WM treatments	$8,500	ibrutinib (Imbruvica), acalabrutinib (Calquence), zanubrutinib (Brukinsa)	75%	10%
Emerging BTK inhibitors	$2,200	Pirtobrutinib, evobrutinib, and others	10%	25%
Overall BTK market	$10,700	Multiple	-	-

Source: GlobalData, 2023.[1]

---

Market Dynamics for Pirtobrutinib

Clinical Positioning and Differentiators

• Mechanism of Action: Reversible BTK inhibitor binds non-covalently, potentially reducing resistance associated with C481 mutations, common with ibrutinib.

• Clinical Data:

  • Efficacy: Early-phase data demonstrates ORRs (objective response rates) ranging from 60-75% in heavily pretreated R/R MCL and CLL.
  • Safety: Favorable tolerability profile, with fewer off-target effects compared to irreversible inhibitors.

• Regulatory Status:

  • FDA Breakthrough Therapy designation for MCL in 2022.
  • Phase 2/3 trials ongoing for multiple indications, with pivotal data expected by end-2023 and submission in 2024.

Market Adoption Factors

• Resistance Management: Key driver for pirtobrutinib, particularly in patients refractory or intolerant to existing BTK inhibitors.

• Combination Potential: Synergistic use with BCL-2 inhibitors (venetoclax), CD20 mAbs (rituximab), and other targeted agents.

• Market Penetration Barriers:

  • Established dominance of ibrutinib, acalabrutinib, and zanubrutinib.
  • Cost and reimbursement landscapes.
  • Clinical trial outcomes strength.

Competitive Landscape

Drug Name	Approval Status	Indications	Key Differentiator	Market Share (2022)	Developing By
Ibrutinib (Imbruvica)	Approved (2013)	CLL, MCL, WM	First-in-class, proven efficacy	65%	AbbVie, Johnson & Johnson
Acalabrutinib (Calquence)	Approved (2017)	CLL, MCL	Selective, fewer off-target effects	15%	AstraZeneca
Zanubrutinib (Brukinsa)	Approved (2019)	CLL, WM, MCL	High selectivity, reduced adverse events	10%	BeiGene
Pirtobrutinib	Investigational	Multiple B-cell malignancies	Reversible binding, resistance overcomes	Limited (~1%) initially	Eli Lilly

---

Financial Trajectory Projections

Year	Pre-approval Revenue	Post-approval Revenue	Key Assumptions
2023	$0.2M (clinical trial licensing)	~$0.5B (peak)	US/EU approvals, label expansion, market uptake accelerating
2024	$1M	$1.2B	Launch in US, incremental market expansion
2025-2027	Accelerating to $2-3B	$2-4B	Global expansion, new indications, combination therapy approvals

Note: These estimates assume successful clinical trial outcomes, timely regulatory approval, and effective commercialization.

Investment Considerations

• Market Entry Timing: Approval anticipated by late 2023 or early 2024 could catalyze rapid revenue growth.

• Pricing Strategy: Premium pricing for targeted therapies, with potential discounts to ensure market penetration.

• Partnerships and Licensing: Strategic alliances with pharma companies could enhance market access and distribution.

• Intellectual Property (IP): Patent life extending into the 2030s, with ongoing patent filings related to formulation, use, and combination methods.

---

Comparison with Market Leaders

Parameter	Ibrutinib	Acalabrutinib	Zanubrutinib	Pirtobrutinib (Projected)
Approval Year	2013	2017	2019	2023/2024 (expected)
Indications	CLL, MCL, WM, others	CLL, MCL	WM, CLL, MCL	Multiple B-cell malignancies
Mechanism	Irreversible, covalent binding	Irreversible, covalent binding	Irreversible, covalent binding	Reversible, non-covalent binding
Resistance Profile	C481S mutations reduce efficacy	Resistance issues emerging	Similar resistance issues	Designed to overcome resistance
Market Penetration	Dominant early leader	Growing niche	Niche/growing	Entry stage, high potential

---

Regulatory Pathway and Timeline

Milestone	Expected Date	Details
Phase 2 trial completion	Q2 2023	Data for pivotal study submission
NDA/BLA submission	Q2 2024	Based on favorable trial outcomes
Regulatory review completion	Q4 2024	Potential approval for one or more indications
Full market launch	Q1 2025	Post-approval commercialization

---

Key Market Risks

Risk Factor	Potential Impact	Mitigation Strategies
Clinical failure or delays	No regulatory approval, lost market opportunity	Robust trial design, early data transparency
Competitive dynamics	Market saturation, aggressive pricing from incumbents	Differentiation through safety/efficacy
Pricing and reimbursement	Reimbursement hurdles could limit access	Early payer engagement, pharmacoeconomic studies
Emerging resistance mechanisms	Reduced efficacy over time	Combination therapies, next-generation inhibitors

---

Key Takeaways

• Pirtobrutinib offers a promising therapeutic advance as a reversible BTK inhibitor addressing resistance and tolerability issues.
• The drug is in late-stage clinical trials with projected US/EU approval within 12-24 months, opening substantial commercial opportunities.
• Its success depends on overcoming market incumbents through clear clinical benefits and strategic partnerships.
• The expanding indications and potential combination treatments suggest a trajectory toward multi-billion-dollar annual sales, contingent on regulatory and clinical progress.
• Investors must manage risks related to clinical efficacy, market adoption, competitive pressures, and reimbursement landscapes.

---

FAQs

1. How does pirtobrutinib compare to existing BTK inhibitors?
Pirtobrutinib's reversible, non-covalent binding mechanism allows it to potentially overcome resistance mutations (e.g., C481S) that limit covalent inhibitors like ibrutinib. It also exhibits a favorable safety profile, with fewer off-target effects.

2. When is pirtobrutinib expected to receive FDA approval?
Based on current trial timelines and data, the FDA approval is projected for late 2023 or early 2024, with subsequent commercialization beginning in 2024.

3. What are the main competitive advantages of pirtobrutinib?
Key advantages include its ability to target resistant BTK variants, improved safety/tolerability, and potential for combination therapy applications—especially in patients refractory or intolerant to existing agents.

4. Which markets will be prioritized for commercialization?
Initial focus will be on the US and Europe, with indications for MCL, CLL, and WM. Broader approvals and indications could expand into Asia-Pacific, Latin America, and other regions.

5. What are potential hurdles for market penetration?
Challenges include the entrenched market leaders, pricing negotiations, reimbursement hurdles, and proving clinical superiority in head-to-head studies.

---

References

[1] GlobalData. BTK Inhibitors Market Analysis, 2023.